Orexigen Therapeutics (OREX) 4.97 $OREX
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Thu Jul 31, 7:00AM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the second quarter 2014, on Thursday, August 7, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
Orexigen Receives CHMP Day 180 List of Outstanding Issues
PR Newswire - Wed Jul 30, 7:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release (SR) / bupropion SR) is an investigational drug candidate being evaluated for weight loss.
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jul 18, 9:09AM CDT
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Anti-Obesity Drugs Market 2014-2020 - Global Strategic Business Report
M2 - Thu Jul 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8gsfc/antiobesity) has announced the addition of the "Anti-Obesity Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as: - Arena Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Novo Nordisk - Orexigen Therapeutics, Inc. - Rhythm Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Scenario 3. Market Trends, Drivers And Challenges 4. Select Pipeline Drug Candidates 5. Select Scientific Breakthroughs 6. Obesity An Introduction 7. Obesity Treatment 8. Anti-Obesity Drugs An Insight 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 33 (including Divisions/Subsidiaries 34) - The United States (14) - Japan (4) - Europe (
- The United Kingdom (3) - Rest of Europe (5) - Asia-Pacific (Excluding Japan) ( For more information visit http://www.researchandmarkets.com/research/n8...ntiobesity
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks." -- Arena Pharmaceuticals CEO Jack...
Critical Alerts For Regeneron Pharmaceuticals, Orexigen Therapeutics, News Corp, BorgWarner, and Michael Kors Released By InvestorsObserver
PR Newswire - Fri Jul 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for REGN, OREX, NWSA, BWA, and KORS.
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
3 Stocks Even Volatility-Loving Nasdaq Investors Hate
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 02, 5:16PM CDT
Another month is in the books for the volatile and highly tech-centric Nasdaq Composite , and surprise, surprise -- it was a positive month! Out of the 21 trading sessions in June, the Nasdaq advanced on two-thirds of all days and gained 3.9% for...
The Next Orphan Drug Multibagger and Future Obesity Champion?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 5:22PM CDT
The newest kid on the biotech block is Zafgen , which successfully IPO'd this month. Shares popped over 20% on its opening day and have held strong since. Zafgen has a small pipeline, but it does have a drug for Prader-Willi Syndrome, an orphan...
3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir
Alexander Maxwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
With so many FDA decisions coming out in a few months, it is an exciting time for biotech investors. For all three of these stocks -- Spectrum Pharmaceuticals , Orexigen Therapeutics , and Avanir Pharmaceuticals -- obtaining FDA approval will...
Are Investors Wrong About Orexigen Therapeutics?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 4:30PM CDT
A rising short interest can be a good sign that its time to sell a stock. By the same token, short-sellers are wrong on occasion, leading to large upward movements in share price due to a so-called "short squeeze." Shares of antiobesity drugmaker ...
Health Care Sector Equities Scrutiny -- Research on OPKO Health, Orexigen Therapeutics, Perrigo, and Auxilium Pharma
PR Newswire - Wed Jun 25, 6:20AM CDT
On Tuesday, June 24, 2014, the NASDAQ Composite ended at 4,350.36, down 0.42%, the Dow Jones Industrial Average declined 0.70% to finish the day at 16,818.13, and the S&P 500 closed at 1,949.98, down 0.64%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.55, up 0.02%, with the index also advancing 5.16% in the last three months. Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), Perrigo Co. PLC (NYSE: PRGO) and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free technical research on OPK, OREX, PRGO and AUXL can be downloaded upon signing up at:
Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why. VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...
How Bad Is This Delay for Orexigen Therapeutics, Inc?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Orexigen Therapeutics recently announced that the Food and Drug Administration was delaying an approval decision on the biotech's obesity drug Contrave for three months. On the surface, the delay seems harmless. In the press release, Orexigen...
Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date
Brian Orelli, The Motley Fool - Motley Fool - Thu Jun 19, 5:00PM CDT
Investors looking for a piece of the obesity market, but uninterested in the current offerings -- Arena Pharmaceuticals , VIVUS , and Orexigen -- have a new opportunity: Zafgen debuted on the NASDAQ today, having raised $96 million in its...
Why Zafgen Inc. Shares Roared Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 19, 2:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zafgen , a clinical-stage...
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.
Clinical Studies, Review Extensions, Appointments, and Conference Schedules - Analyst Notes on Karyopharm, Orexigen, INSYS, bluebird bio and AMAG Pharmaceuticals
PR Newswire - Wed Jun 18, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Orexigen Therapeutics, Inc. (NASDAQ: OREX), INSYS Therapeutics, Inc. (NASDAQ: INSY), bluebird bio, Inc. (NASDAQ: BLUE) and AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3825-100free.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Thu Jul 31, 7:00AM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the second quarter 2014, on Thursday, August 7, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
Orexigen Receives CHMP Day 180 List of Outstanding Issues
PR Newswire - Wed Jul 30, 7:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release (SR) / bupropion SR) is an investigational drug candidate being evaluated for weight loss.
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jul 18, 9:09AM CDT
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Anti-Obesity Drugs Market 2014-2020 - Global Strategic Business Report
M2 - Thu Jul 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8gsfc/antiobesity) has announced the addition of the "Anti-Obesity Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as: - Arena Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Novo Nordisk - Orexigen Therapeutics, Inc. - Rhythm Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Scenario 3. Market Trends, Drivers And Challenges 4. Select Pipeline Drug Candidates 5. Select Scientific Breakthroughs 6. Obesity An Introduction 7. Obesity Treatment 8. Anti-Obesity Drugs An Insight 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 33 (including Divisions/Subsidiaries 34) - The United States (14) - Japan (4) - Europe (
- The United Kingdom (3) - Rest of Europe (5) - Asia-Pacific (Excluding Japan) ( For more information visit http://www.researchandmarkets.com/research/n8...ntiobesity Arena Pharmaceuticals Inc. Still Down After CEO's Sale
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks." -- Arena Pharmaceuticals CEO Jack...
Critical Alerts For Regeneron Pharmaceuticals, Orexigen Therapeutics, News Corp, BorgWarner, and Michael Kors Released By InvestorsObserver
PR Newswire - Fri Jul 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for REGN, OREX, NWSA, BWA, and KORS.
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
3 Stocks Even Volatility-Loving Nasdaq Investors Hate
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 02, 5:16PM CDT
Another month is in the books for the volatile and highly tech-centric Nasdaq Composite , and surprise, surprise -- it was a positive month! Out of the 21 trading sessions in June, the Nasdaq advanced on two-thirds of all days and gained 3.9% for...
The Next Orphan Drug Multibagger and Future Obesity Champion?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 5:22PM CDT
The newest kid on the biotech block is Zafgen , which successfully IPO'd this month. Shares popped over 20% on its opening day and have held strong since. Zafgen has a small pipeline, but it does have a drug for Prader-Willi Syndrome, an orphan...
3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir
Alexander Maxwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
With so many FDA decisions coming out in a few months, it is an exciting time for biotech investors. For all three of these stocks -- Spectrum Pharmaceuticals , Orexigen Therapeutics , and Avanir Pharmaceuticals -- obtaining FDA approval will...
Are Investors Wrong About Orexigen Therapeutics?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 4:30PM CDT
A rising short interest can be a good sign that its time to sell a stock. By the same token, short-sellers are wrong on occasion, leading to large upward movements in share price due to a so-called "short squeeze." Shares of antiobesity drugmaker ...
Health Care Sector Equities Scrutiny -- Research on OPKO Health, Orexigen Therapeutics, Perrigo, and Auxilium Pharma
PR Newswire - Wed Jun 25, 6:20AM CDT
On Tuesday, June 24, 2014, the NASDAQ Composite ended at 4,350.36, down 0.42%, the Dow Jones Industrial Average declined 0.70% to finish the day at 16,818.13, and the S&P 500 closed at 1,949.98, down 0.64%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.55, up 0.02%, with the index also advancing 5.16% in the last three months. Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), Perrigo Co. PLC (NYSE: PRGO) and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free technical research on OPK, OREX, PRGO and AUXL can be downloaded upon signing up at:
Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why. VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...
How Bad Is This Delay for Orexigen Therapeutics, Inc?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Orexigen Therapeutics recently announced that the Food and Drug Administration was delaying an approval decision on the biotech's obesity drug Contrave for three months. On the surface, the delay seems harmless. In the press release, Orexigen...
Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date
Brian Orelli, The Motley Fool - Motley Fool - Thu Jun 19, 5:00PM CDT
Investors looking for a piece of the obesity market, but uninterested in the current offerings -- Arena Pharmaceuticals , VIVUS , and Orexigen -- have a new opportunity: Zafgen debuted on the NASDAQ today, having raised $96 million in its...
Why Zafgen Inc. Shares Roared Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 19, 2:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zafgen , a clinical-stage...
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.
Clinical Studies, Review Extensions, Appointments, and Conference Schedules - Analyst Notes on Karyopharm, Orexigen, INSYS, bluebird bio and AMAG Pharmaceuticals
PR Newswire - Wed Jun 18, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Orexigen Therapeutics, Inc. (NASDAQ: OREX), INSYS Therapeutics, Inc. (NASDAQ: INSY), bluebird bio, Inc. (NASDAQ: BLUE) and AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3825-100free.
